Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.1 -0.01 (-0.9%) Market Cap: 281.12 Mil Enterprise Value: 163.71 Mil PE Ratio: 0 PB Ratio: 11.00 GF Score: 70/100

Q2 2019 Adaptimmune Therapeutics PLC Earnings Call Transcript

Aug 01, 2019 / 12:00PM GMT
Release Date Price: $2.95 (-10.33%)
Operator

Good morning and welcome to the second quarter of 2019 Adaptimmune earnings conference call. My name is Carla, and I will be your conference operator today. (Operator Instructions)

And now I would like to turn the call over to Juli Miller. Go ahead, please.

Juli P. Miller
Adaptimmune Therapeutics plc - Director of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our second quarter 2019 financial results and other business update. We issued 2 press releases earlier this morning, and I would ask you to please review the full text of our forward-looking statements there. As a brief reminder, we anticipate making projections during this call and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC.

James Noble, our Chief Executive Officer; Adrian Rawcliffe, incoming Adaptimmune's CEO; and Rafael Amado, our President of Research and Development are with me for the prepared portion of this call. Bill Bertrand, our Chief Operating Officer; Helen Tayton

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot